{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"TTP: time from date of first dose to date of first documentation of PD as defined by standard disease criteria. PD was defined as increase of \\>25% from lowest response value in any one or more of following: a) Serum M-component and/or (the absolute increase must be \\>0.5 grams per deciliter \\[g/dL\\]). b) Urine M-component and/or (the absolute increase must be \\>200 mg/24 h). c) Only in participants without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be \\>10 milligrams per deciliter (mg/dL). d) Bone marrow plasma cell percentage; the absolute percentage must be \\>10%. e) Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. f) Development of hypercalcaemia (corrected serum calcium \\>11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder.","groups":[{"description":"Participants were planned to receive TAK-981 recommended phase 2 dose (RP2D), infusion, intravenously, in combination with an anti-CD38 antibody (mezagitamab or daratumumab and hyaluronidase-fihj), injection, subcutaneously, for up to 24 cycles or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG000","title":"Phase 2: TAK-981 (RP2D) + Selected Anti-CD38 Antibody"}],"populationDescription":"The study was terminated after completion of Phase 1b Part 1, therefore, no participants were enrolled in Phase 2 part of the study. Hence, the data for this outcome measure could not collected, analyzed and reported.","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Phase 2: TTP Based on IMWG Criteria","type":"SECONDARY"}